MXPA04008277A - Uso de ribozimas en la deteccion de agentes casuales. - Google Patents
Uso de ribozimas en la deteccion de agentes casuales.Info
- Publication number
- MXPA04008277A MXPA04008277A MXPA04008277A MXPA04008277A MXPA04008277A MX PA04008277 A MXPA04008277 A MX PA04008277A MX PA04008277 A MXPA04008277 A MX PA04008277A MX PA04008277 A MXPA04008277 A MX PA04008277A MX PA04008277 A MXPA04008277 A MX PA04008277A
- Authority
- MX
- Mexico
- Prior art keywords
- virus
- reovirus
- cells
- ribozyme
- microorganism
- Prior art date
Links
- 108090000994 Catalytic RNA Proteins 0.000 title claims abstract description 79
- 102000053642 Catalytic RNA Human genes 0.000 title claims abstract description 79
- 108091092562 ribozyme Proteins 0.000 title claims abstract description 79
- 238000001514 detection method Methods 0.000 title abstract description 4
- 238000000034 method Methods 0.000 claims abstract description 49
- 244000005700 microbiome Species 0.000 claims abstract description 48
- 239000000203 mixture Substances 0.000 claims abstract description 34
- 210000004027 cell Anatomy 0.000 claims description 153
- 241000702263 Reovirus sp. Species 0.000 claims description 112
- 241000700605 Viruses Species 0.000 claims description 106
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 52
- 108090000623 proteins and genes Proteins 0.000 claims description 36
- 210000005170 neoplastic cell Anatomy 0.000 claims description 21
- 208000015181 infectious disease Diseases 0.000 claims description 19
- 241000702244 Orthoreovirus Species 0.000 claims description 18
- 241000701161 unidentified adenovirus Species 0.000 claims description 17
- 241000700618 Vaccinia virus Species 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 14
- 230000001717 pathogenic effect Effects 0.000 claims description 14
- 231100000255 pathogenic effect Toxicity 0.000 claims description 13
- 241000712461 unidentified influenza virus Species 0.000 claims description 13
- 241000282414 Homo sapiens Species 0.000 claims description 12
- 230000010076 replication Effects 0.000 claims description 12
- 241000700635 Orf virus Species 0.000 claims description 10
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 9
- 238000000926 separation method Methods 0.000 claims description 8
- 101710132601 Capsid protein Proteins 0.000 claims description 6
- 101710094648 Coat protein Proteins 0.000 claims description 6
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims description 6
- 101710125418 Major capsid protein Proteins 0.000 claims description 6
- 101710141454 Nucleoprotein Proteins 0.000 claims description 6
- 101710083689 Probable capsid protein Proteins 0.000 claims description 6
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 208000003322 Coinfection Diseases 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 2
- 231100000676 disease causative agent Toxicity 0.000 claims 1
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 description 34
- 206010028980 Neoplasm Diseases 0.000 description 30
- 238000002360 preparation method Methods 0.000 description 27
- 239000003795 chemical substances by application Substances 0.000 description 26
- 230000037361 pathway Effects 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 20
- 230000004913 activation Effects 0.000 description 17
- 230000000120 cytopathologic effect Effects 0.000 description 15
- 241000700584 Simplexvirus Species 0.000 description 14
- 102000014150 Interferons Human genes 0.000 description 13
- 108010050904 Interferons Proteins 0.000 description 13
- 244000309459 oncolytic virus Species 0.000 description 11
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 10
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 10
- 230000002238 attenuated effect Effects 0.000 description 10
- 208000008104 Reoviridae Infections Diseases 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 229940079322 interferon Drugs 0.000 description 9
- 108060006698 EGF receptor Proteins 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 102000001301 EGF receptor Human genes 0.000 description 7
- 230000003197 catalytic effect Effects 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000000813 microbial effect Effects 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 210000002845 virion Anatomy 0.000 description 6
- 101150096316 5 gene Proteins 0.000 description 5
- 241000711404 Avian avulavirus 1 Species 0.000 description 5
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 5
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 5
- 241000700639 Parapoxvirus Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 208000035269 cancer or benign tumor Diseases 0.000 description 5
- 210000000234 capsid Anatomy 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000001243 protein synthesis Methods 0.000 description 5
- 108700042226 ras Genes Proteins 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 4
- 101150040459 RAS gene Proteins 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229940047124 interferons Drugs 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 101150091263 E3L gene Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 208000007514 Herpes zoster Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101710128560 Initiator protein NS1 Proteins 0.000 description 3
- 101150076606 K3L gene Proteins 0.000 description 3
- 101710144127 Non-structural protein 1 Proteins 0.000 description 3
- 102000029797 Prion Human genes 0.000 description 3
- 108091000054 Prion Proteins 0.000 description 3
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 3
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 3
- 241000251131 Sphyrna Species 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000005860 defense response to virus Effects 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000000174 oncolytic effect Effects 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 108090000317 Chymotrypsin Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108090001102 Hammerhead ribozyme Proteins 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- 206010027457 Metastases to liver Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091008606 PDGF receptors Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960002376 chymotrypsin Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 229940029575 guanosine Drugs 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 239000003471 mutagenic agent Substances 0.000 description 2
- 231100000707 mutagenic chemical Toxicity 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 108700025694 p53 Genes Proteins 0.000 description 2
- 229940118537 p53 inhibitor Drugs 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 241001516406 Avian orthoreovirus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 241000283725 Bos Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101710201734 E3 protein Proteins 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 208000037262 Hepatitis delta Diseases 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 101100508081 Human herpesvirus 1 (strain 17) ICP34.5 gene Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101150033828 NS1 gene Proteins 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 101150027249 RL1 gene Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 241000223892 Tetrahymena Species 0.000 description 1
- 241000248384 Tetrahymena thermophila Species 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002962 chemical mutagen Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 244000309457 enveloped RNA virus Species 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 108700021358 erbB-1 Genes Proteins 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 108090001052 hairpin ribozyme Proteins 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 208000029570 hepatitis D virus infection Diseases 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000003303 reheating Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000008299 viral mechanism Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/30—Phosphoric diester hydrolysing, i.e. nuclease
- C12Q2521/337—Ribozyme
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/14—Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36073002P | 2002-02-28 | 2002-02-28 | |
| PCT/CA2003/000264 WO2003072811A2 (en) | 2002-02-28 | 2003-02-26 | The use of ribozymes in the detection of adventitious agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04008277A true MXPA04008277A (es) | 2004-11-10 |
Family
ID=27766245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04008277A MXPA04008277A (es) | 2002-02-28 | 2003-02-26 | Uso de ribozimas en la deteccion de agentes casuales. |
Country Status (16)
| Country | Link |
|---|---|
| EP (2) | EP2439286A1 (OSRAM) |
| JP (3) | JP4369243B2 (OSRAM) |
| AR (1) | AR038849A1 (OSRAM) |
| AT (1) | ATE519860T1 (OSRAM) |
| AU (1) | AU2003206587B2 (OSRAM) |
| BR (1) | BR0307882A (OSRAM) |
| CA (1) | CA2374388C (OSRAM) |
| DE (1) | DE03704136T1 (OSRAM) |
| DK (1) | DK1481084T3 (OSRAM) |
| ES (1) | ES2241506T3 (OSRAM) |
| MX (1) | MXPA04008277A (OSRAM) |
| NZ (1) | NZ534488A (OSRAM) |
| TR (1) | TR200501513T3 (OSRAM) |
| TW (1) | TWI329132B (OSRAM) |
| WO (1) | WO2003072811A2 (OSRAM) |
| ZA (1) | ZA200406231B (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1306959C (zh) * | 2004-09-21 | 2007-03-28 | 中国科学院武汉病毒研究所 | 草鱼呼肠孤病毒抗原亚单位疫苗制备方法 |
| US10668119B2 (en) | 2005-08-01 | 2020-06-02 | Virocure, Inc. | Attenuated reovirus |
| WO2007099401A2 (en) | 2005-08-01 | 2007-09-07 | University Technologies International, Inc. | Oncolytic attenuated reoviruses for treatment of proliferative disorders |
| US10369171B2 (en) | 2007-03-13 | 2019-08-06 | Virocure, Inc. | Attenuated reoviruses for selection of cell populations |
| TW201738562A (zh) * | 2009-05-28 | 2017-11-01 | 亞培生物股份有限公司 | 體外病原體檢驗技術 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5254678A (en) | 1987-12-15 | 1993-10-19 | Gene Shears Pty. Limited | Ribozymes |
| US5168053A (en) | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
| US5225337A (en) | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Ribozyme compositions and methods for use |
| US5225347A (en) | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Therapeutic ribozyme compositions and expression vectors |
| US5631115A (en) | 1992-07-02 | 1997-05-20 | Sankyo Company, Limited | Looped, hairpin ribozyme |
| WO1994013791A1 (en) * | 1992-12-04 | 1994-06-23 | Innovir Laboratories, Inc. | Regulatable nucleic acid therapeutic and methods of use thereof |
| DK0931830T3 (da) | 1993-02-16 | 2001-06-11 | Onyx Pharma Inc | Cytopatiske vira til terapi og profylakse af neoplasi |
| PT696326E (pt) | 1993-04-30 | 2003-08-29 | Wellstat Biologics Corp | Utilizacao de ndv no fabrico de um medicamento para tratamento do cancro |
| AU5334294A (en) * | 1993-10-15 | 1995-05-04 | Dkfz Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Asymmetric hammerhead ribozymes and nucleotide sequences for their construction |
| US5631359A (en) | 1994-10-11 | 1997-05-20 | Ribozyme Pharmaceuticals, Inc. | Hairpin ribozymes |
| US6107027A (en) * | 1994-12-14 | 2000-08-22 | University Of Washington | Ribozymes for treating hepatitis C |
| US6110461A (en) * | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
| US6136307A (en) | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
| NZ503664A (en) | 1997-10-09 | 2002-08-28 | Pro Virus Inc | A method for purifying an RNA virus comprising generating a clonal virus and purifying the clonal virus by ultracentrifugation without pelleting |
| EP1066312A4 (en) | 1998-03-28 | 2002-01-02 | Univ Utah Res Found | HAMMER HEAD RIBOZYMES AND THEIR DERIVATIVES AS CIRCULAR, HAIRPIN, CIRCULAR / HAIRPIN, LASSO, HAIRPIN / LASSO |
| AU6522599A (en) * | 1998-10-23 | 2000-05-15 | Children's Medical Center Corporation | Use of a self-cleaving rna motif to modulate gene expression |
| AU2001251004A1 (en) * | 2000-03-27 | 2001-10-08 | Smith Kline Beecham Corporation | Detection of viable agents |
| TWI289158B (en) | 2000-08-10 | 2007-11-01 | Oncolytics Biotech Inc | Method of producing infectious reovirus |
-
2002
- 2002-03-04 CA CA002374388A patent/CA2374388C/en not_active Expired - Fee Related
-
2003
- 2003-02-25 TW TW092103911A patent/TWI329132B/zh not_active IP Right Cessation
- 2003-02-26 BR BR0307882-5A patent/BR0307882A/pt not_active IP Right Cessation
- 2003-02-26 EP EP11176991A patent/EP2439286A1/en not_active Withdrawn
- 2003-02-26 WO PCT/CA2003/000264 patent/WO2003072811A2/en not_active Ceased
- 2003-02-26 DE DE03704136T patent/DE03704136T1/de active Pending
- 2003-02-26 MX MXPA04008277A patent/MXPA04008277A/es active IP Right Grant
- 2003-02-26 TR TR2005/01513T patent/TR200501513T3/xx unknown
- 2003-02-26 AR ARP030100637A patent/AR038849A1/es unknown
- 2003-02-26 AU AU2003206587A patent/AU2003206587B2/en not_active Ceased
- 2003-02-26 EP EP03704136A patent/EP1481084B1/en not_active Expired - Lifetime
- 2003-02-26 DK DK03704136.5T patent/DK1481084T3/da active
- 2003-02-26 NZ NZ534488A patent/NZ534488A/en unknown
- 2003-02-26 ES ES03704136T patent/ES2241506T3/es not_active Expired - Lifetime
- 2003-02-26 JP JP2003571491A patent/JP4369243B2/ja not_active Expired - Fee Related
- 2003-02-26 AT AT03704136T patent/ATE519860T1/de not_active IP Right Cessation
-
2004
- 2004-08-04 ZA ZA2004/06231A patent/ZA200406231B/en unknown
-
2008
- 2008-09-12 JP JP2008235697A patent/JP2009005712A/ja not_active Withdrawn
-
2012
- 2012-03-29 JP JP2012077593A patent/JP5615865B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP4369243B2 (ja) | 2009-11-18 |
| TW200404099A (en) | 2004-03-16 |
| AU2003206587A1 (en) | 2003-09-09 |
| BR0307882A (pt) | 2004-12-28 |
| NZ534488A (en) | 2008-04-30 |
| ES2241506T1 (es) | 2005-11-01 |
| HK1067664A1 (en) | 2005-04-15 |
| AU2003206587B2 (en) | 2007-03-15 |
| EP1481084B1 (en) | 2011-08-10 |
| CA2374388A1 (en) | 2003-08-28 |
| WO2003072811A2 (en) | 2003-09-04 |
| CA2374388C (en) | 2005-07-12 |
| EP1481084A2 (en) | 2004-12-01 |
| WO2003072811A3 (en) | 2004-02-05 |
| JP5615865B2 (ja) | 2014-10-29 |
| EP2439286A1 (en) | 2012-04-11 |
| DK1481084T3 (da) | 2011-09-26 |
| ZA200406231B (en) | 2005-11-30 |
| TR200501513T3 (tr) | 2005-06-21 |
| JP2012125257A (ja) | 2012-07-05 |
| AR038849A1 (es) | 2005-01-26 |
| JP2009005712A (ja) | 2009-01-15 |
| TWI329132B (en) | 2010-08-21 |
| ES2241506T3 (es) | 2011-12-13 |
| JP2005518797A (ja) | 2005-06-30 |
| DE03704136T1 (de) | 2005-12-15 |
| ATE519860T1 (de) | 2011-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Elankumaran et al. | Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death | |
| AU2007207860B2 (en) | Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells with Reovirus | |
| Ammayappan et al. | Nonvirion protein of novirhabdovirus suppresses apoptosis at the early stage of virus infection | |
| Shmulevitz et al. | Reovirus variants with mutations in genome segments S1 and L2 exhibit enhanced virion infectivity and superior oncolysis | |
| Sheng et al. | Malignant transformation of Epstein-Barr virus-negative Akata cells by introduction of the BARF1 gene carried by Epstein-Barr virus | |
| JP5615865B2 (ja) | 外来性の物質の検出におけるリボザイムの使用 | |
| US20020061298A1 (en) | Method for optimally delivering virus to a solid tumor mass | |
| CA2408251C (en) | Clearance of neoplastic cells from mixed cellular compositions using viruses | |
| US8609331B2 (en) | Use of ribozymes in the detection of adventitious agents | |
| CA2435967A1 (en) | Reovirus for the treatment of lymphoid malignancies | |
| HK1164943A (en) | The use of ribozymes in the detection of adventitious agents | |
| HK1067664B (en) | The use of ribozymes in the detection of adventitious agents | |
| CN113692443A (zh) | 包含nc886的用于增强溶瘤病毒活性或用于促进溶瘤病毒生产的组合物 | |
| Maxwell | The mechanism and kinetics of reovirus T1-and T3-induced apoptosis of human colon and pancreatic cancer cells | |
| CA2605803A1 (en) | Clearance of neoplastic cells from mixed cellular compositions using viruses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |